30 closest matches · ranked by relevance
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Lung Cancer
Primary: The Difference of Diagnostic Value of ENB-GS-TBLB as Compared to GS-TBLB — 34; 25; 5; 16 participants — p=0.019
Peripheral Solitary Pulmonary Nodule or Tuberculoma
Primary: Comparing the Inflammatory Markers During the Operation After the Intervention of the Each Group — 33; 35; 39; 42 pg/L — p=0.025
Peripheral Pulmonary Nodules
Primary: Feasibility — 24 participants
Lung Nodule
Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003
Lung; Node
Primary: Number of Participants With Device or Procedure Related Adverse Events — 2 Participants
Tuberculosis · AIDS-related Complex
Primary: Sputum Conversion — 36; 60; 36 percentage of participants
Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants
Lung Neoplasm · Thoracic Surgery, Video-Assisted
Primary: Accuracy of Lung Nodule Localization — 9.6; 8.7 mm
Sarcoidosis
Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…
Pulmonary Sarcoidosis · Lung Function
Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters
Lung Cancer
Primary: Safety Measurement — 0; 0; 0; 0 Adverse events
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
Current Smoker · Former Smoker · Multiple Pulmonary Nodules
Primary: Change in the Sum of Longest Diameters of Baseline Target Nodules (Person-specific Analysis) — 0.3; -0.12 millimeter (mm)
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Lung Cancer · Lung Cancer Metastatic
Primary: Safety: Number of Participants With at Least One Adverse Event — 10 Participants — p=<0.05
Non Small Cell Lung Cancer
Primary: Change in the Mean Number of Infiltrating Absolute Cluster of Differentiation 3 (CD3+) T Cells/ μm2 — 2976.00007; 3768.74373 CD3+ T cells/ μm2
Cigarette Smoker · Current Smoker · Former Smoker
Primary: Diagnostic Performance Metrics (Sensitivity, Specificity, PPV, NPV, and Accuracy) of Ultrasonography and Capnography for Malignant Lung Nodules — 100; 70; 100; 100…
Lung Cancer
Primary: Number CT- Detected Lung Nodules by Participant — 12; 14; 26; 19 lung nodules
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Tuberculosis · Multi-Drug Resistant Tuberculosis
Primary: Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). — 8.11; 10.08; 6.64; 7.24 reader score
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Non-small Cell Lung Cancer (NSCLC) · Lung Metastasis
Primary: Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor — 3; 0; 1; 1 Participants
Signs and Symptoms
Primary: Sensitivity — 53 percentage of positive scans
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Pulmonary Disease
Primary: Time to Achieve Hemostasis After Obtaining Cryobiopsy — 146.55; 132.25 seconds — p=0.7878
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
Cancer, Lung · Cancer, Metastatic to Lung
Primary: Number of Participants With AEs Related to the Emprint™ Ablation Catheter Kit With Thermosphere™ Technology — 1 Participants
Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8
Primary: 6-month CT Assessment (Tumor Response Per mRECIST) — 1; 36; 2; 1 Participants